Today in News History
On July 11, several notable moments in the history of News stand out. In 154, Bardaisan, Syrian astrologer, scholar, and philosopher (died 222) was born. In 1953, Ivan Toms, South African physician and activist (died 2008) was born. In 1955, Balaji Sadasivan, Singaporean neurosurgeon and politician, Singaporean Minister of Health (died 2010) was born. In 1961, Antony Jenkins, English banker and businessman was born. In 1994, Gary Kildall, American computer scientist, founded Digital Research (born 1942) passed away. In 1999, Jan Sloot, Dutch computer scientist and electronics technician (born 1945) passed away. In 2007, Ed Mirvish, American-Canadian businessman and philanthropist, founded Honest Ed's (born 1914) passed away. In 2008, Michael E. DeBakey, American surgeon and educator (born 1908) passed away. In 2013, Emik Avakian, Iranian-American inventor (born 1923) passed away. In 2015, André Leysen, Belgian businessman (born 1927) passed away. Together, these milestones provide historical context for today's news news and ongoing narratives.
Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?
The company recently wowed investors with clinical trial results.
Narrative Intelligence Brief
This article was published by The Motley Fool, a source frequently categorized with a lean left bias based in United States of America. Our narrative intelligence engine continuously monitors coverage from this outlet to track framing, bias, and rhetorical patterns. Our initial algorithmic scan of this specific piece did not flag high-confidence rhetorical techniques, suggesting a generally straightforward reporting style or neutral framing. By understanding the editorial perspective of The Motley Fool, readers can better contextualize the information presented and compare it across our broader media matrix to find the real narrative.
More from The Motley Fool
July 11, 2026
2 Beaten-Down Stocks That Still Aren't Worth Buying
July 11, 2026
An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors?
July 11, 2026
Oil Is Below $76. So Why Is Bitcoin Still Below $65,000?
July 11, 2026
5 Top AI Stocks Investors Own on Robinhood
July 11, 2026
What Does the Sale of NuScale Stock by the CFO Mean to Investors?
Analysis Methodology
This narrative analysis was generated using the CoDataLab Global Intelligence Engine. Our proprietary AI scans thousands of cross-border sources to identify sentiment patterns, framing techniques, and potential media bias. While AI provides the data-driven foundation, our objective is to empower readers with additional context beyond the standard headline.The content displayed above is a structured summary designed for rapid information processing. For the full original report, please visit the source outlet.More Coverage
Discussion
"wimbledon"
Jannik Sinner vs. Alexander Zverev odds, prediction: 2026 Wimbledon men's final picks by proven expert
Kate hails ‘inspirational’ Wimbledon finalist who plays through cancer treatment
Jeremy Clarkson hits out at Nigel Farage’s ‘silly temper tantrum’ as he speaks out on by-election drama
How other outlets are covering this story
Compare narratives across 4 related reports from 4 sources. Real Narrative News aggregates the coverage spectrum so you can see who emphasises what — bias tags reflect the outlet, not the story.
Coverage bias distribution
4 sources
Left 25%
Center 25%
Right 50%
The Motley Fool
· Jul 10, 2026
Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?
Additional blockbuster drugs may be on the horizon.
Seeking Alpha
· Jun 25, 2026
Crinetics Pharmaceuticals: 'Buy' On Palsonify Market Expansion And Atumelnant Advancements
Crinetics Pharmaceuticals: 'Buy' On Palsonify Market Expansion And Atumelnant Advancements
The Hindu BusinessLine
· Jul 7, 2026
Stock to buy today: Glenmark Pharmaceuticals (₹2,270) – BUY
Glenmark Pharmaceuticals share price can rise to 2,500
The Eastern Herald
· Jul 5, 2026
FDA Clears a Transplant Therapy Built to Cut Chronic GVHD From 44% to 13%
The FDA approved Tregzi, Orca Bio's engineered cell therapy, after a 187-patient trial found it cut moderate-to-severe chronic graft-versus-host disease from 44 with standard transplants to 13. The tradeoff patients now face is a newer therapy without years of follow-up data behind it.
Topics:
Related coverage for "Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?": The Motley Fool — Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?. Seeking Alpha — Crinetics Pharmaceuticals: 'Buy' On Palsonify Market Expansion And Atumelnant Advancements. The Hindu BusinessLine — Stock to buy today: Glenmark Pharmaceuticals (₹2,270) – BUY. The Eastern Herald — FDA Clears a Transplant Therapy Built to Cut Chronic GVHD From 44% to 13%